NASDAQ:KNSA Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $10.76 +0.06 (+0.56%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$10.64▼$11.0450-Day Range$10.70▼$14.5252-Week Range$7.36▼$17.19Volume800,250 shsAverage Volume459,650 shsMarket Capitalization$750.51 millionP/E Ratio4.15Dividend YieldN/APrice Target$20.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kiniksa Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside85.9% Upside$20.00 Price TargetShort InterestHealthy3.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.40Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector87th out of 1,004 stocksPharmaceutical Preparations Industry31st out of 489 stocks 3.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Kiniksa Pharmaceuticals has a forecasted upside of 85.9% from its current price of $10.76.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.61% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently decreased by 7.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 3.0 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kiniksa Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders54.57% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.98% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.59) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 4.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 4.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 79.52.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kiniksa Pharmaceuticals (NASDAQ:KNSA) StockKiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.Read More Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KNSA Stock News HeadlinesApril 1, 2023 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Down 3.9%March 31, 2023 | finance.yahoo.comAfter Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA)April 1, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 11, 2023 | finance.yahoo.comThe Top 7 Growth Stocks in BiotechMarch 10, 2023 | nasdaq.comBlackRock Now Owns 4.90% of Kiniksa Pharmaceuticals (KNSA)March 1, 2023 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue EstimatesFebruary 28, 2023 | finance.yahoo.comKiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio ExecutionFebruary 28, 2023 | msn.comEarnings Scheduled For February 28, 2023April 1, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 27, 2023 | finance.yahoo.comFurther weakness as Kiniksa Pharmaceuticals (NASDAQ:KNSA) drops 9.0% this week, taking three-year losses to 32%February 27, 2023 | finance.yahoo.comKiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023January 25, 2023 | seekingalpha.comKNSA Kiniksa Pharmaceuticals, Ltd.January 9, 2023 | finance.yahoo.comKiniksa Pharmaceuticals Provides Corporate and Portfolio UpdateJanuary 3, 2023 | finance.yahoo.comKiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 3, 2022 | seekingalpha.comKiniksa Pharmaceuticals: This Enterprising BioTech Should Be On Your Stock WatchlistNovember 30, 2022 | finance.yahoo.comKiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap ConferenceNovember 24, 2022 | finance.yahoo.comKiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx ConferenceNovember 10, 2022 | msn.comAre Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?November 10, 2022 | finance.yahoo.comAre Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?November 7, 2022 | finance.yahoo.comRecent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's WhyNovember 7, 2022 | finance.yahoo.comWall Street Analysts Predict a 73% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should KnowNovember 1, 2022 | marketwatch.comKiniksa Pharmaceuticals Shares Rally After 3Q Update >KNSANovember 1, 2022 | msn.comRecap: Kiniksa Pharmaceuticals Q3 EarningsNovember 1, 2022 | finance.yahoo.comKiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 1, 2022 | finance.yahoo.comKiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022October 5, 2022 | finance.yahoo.comWhat Makes Kiniksa Pharmaceuticals, Ltd. (KNSA) a Good Fit for "Trend Investing"September 21, 2022 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's WhySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KNSA Company Calendar Last Earnings11/01/2021Today4/01/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees215Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+85.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.59 Trailing P/E Ratio4.15 Forward P/E RatioN/A P/E GrowthN/ANet Income$183.36 million Net Margins83.28% Pretax Margin5.01% Return on Equity2.18% Return on Assets1.76% Debt Debt-to-Equity RatioN/A Current Ratio5.16 Quick Ratio4.71 Sales & Book Value Annual Sales$220.18 million Price / Sales3.41 Cash Flow$2.57 per share Price / Cash Flow4.18 Book Value$5.68 per share Price / Book1.89Miscellaneous Outstanding Shares69,750,000Free Float31,689,000Market Cap$750.51 million OptionableNot Optionable Beta-0.07 Key ExecutivesSanj K. PatelChairman & Chief Executive OfficerEben P. TessariChief Operating Officer & Senior Vice PresidentMark RagosaChief Financial Officer & Senior Vice PresidentJohn F. PaoliniChief Medical Officer & Senior Vice PresidentChad MorinChief Compliance Officer & Vice PresidentKey CompetitorsInnovivaNASDAQ:INVAPOINT Biopharma GlobalNASDAQ:PNTMerusNASDAQ:MRUSPureTech HealthNASDAQ:PRTCCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCSold 2,609 shares on 2/28/2023Ownership: 0.031%State of WyomingBought 2,087 shares on 2/16/2023Ownership: 0.010%Altshuler Shaham LtdBought 3,956 shares on 2/16/2023Ownership: 0.006%State of Wisconsin Investment BoardBought 3,319 shares on 2/15/2023Ownership: 0.043%Legal & General Group PlcBought 850 shares on 2/15/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions KNSA Stock - Frequently Asked Questions Should I buy or sell Kiniksa Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks. What is Kiniksa Pharmaceuticals' stock price forecast for 2023? 1 analysts have issued 1 year target prices for Kiniksa Pharmaceuticals' shares. Their KNSA share price forecasts range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts. How have KNSA shares performed in 2023? Kiniksa Pharmaceuticals' stock was trading at $14.98 at the beginning of 2023. Since then, KNSA shares have decreased by 28.2% and is now trading at $10.76. View the best growth stocks for 2023 here. Are investors shorting Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 2,520,000 shares, a decline of 7.4% from the February 28th total of 2,720,000 shares. Based on an average daily trading volume, of 374,600 shares, the short-interest ratio is currently 6.7 days. View Kiniksa Pharmaceuticals' Short Interest. When is Kiniksa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our KNSA earnings forecast. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.21. The firm had revenue of $12.10 million for the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 83.28% and a trailing twelve-month return on equity of 2.18%. What ETFs hold Kiniksa Pharmaceuticals' stock? ETFs with the largest weight of Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco DWA Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS), SPDR S&P Biotech ETF (XBI), Hartford Multifactor Small Cap ETF (ROSC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB). What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD). When did Kiniksa Pharmaceuticals IPO? (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Kiniksa Pharmaceuticals' stock symbol? Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA." How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kiniksa Pharmaceuticals' stock price today? One share of KNSA stock can currently be purchased for approximately $10.76. How much money does Kiniksa Pharmaceuticals make? Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $750.51 million and generates $220.18 million in revenue each year. The company earns $183.36 million in net income (profit) each year or $2.59 on an earnings per share basis. How many employees does Kiniksa Pharmaceuticals have? The company employs 215 workers across the globe. How can I contact Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com. This page (NASDAQ:KNSA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.